Shots:

• AbCellera to receive upfront- milestone- and royalties based on the development and commercialization of Abs- emerge under the collaboration
• The expanded collaboration will utilize AbCellera’s technology stack- which includes Trianni Mouse and OrthoMab protein engineering platform
• AbCellera will generate panels of Abs against up to 8 new targets across multiple indications- selected by Gilead

  Ref: BusinessWire | Image: Gilead